Prostate cancer (PC) is the most common male cancer and one of the leading causes of cancer-related morbidity and death. PC affects predominantly the elderly, the highest incidence rates being between the age of 70 and 80 years. Owing in part to the aging population and long natural history of the disease, approximately 54% of men who die of PC are older than 80 years of age. In the natural history of the disease, approximately 10% of patients will develop a castrationresistant prostate cancer (CRPC) which is characterized by a poor prognosis, with a median survival of 2 years. In a recent analysis on PC frequency in the elderly population, it has been shown that older patients are more likely to present with very advanced disease and to have a greater risk of death from PC than other competing causes.

DE VINCENTIS, G., Follacchio, G.a., Frantellizzi, V., Prelaj, A., Farcomeni, A., Giuli, A., et al. (2018). 223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 30(6), 677-680 [10.1007/s40520-017-0826-4].

223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature

FARCOMENI, Alessio;
2018-01-01

Abstract

Prostate cancer (PC) is the most common male cancer and one of the leading causes of cancer-related morbidity and death. PC affects predominantly the elderly, the highest incidence rates being between the age of 70 and 80 years. Owing in part to the aging population and long natural history of the disease, approximately 54% of men who die of PC are older than 80 years of age. In the natural history of the disease, approximately 10% of patients will develop a castrationresistant prostate cancer (CRPC) which is characterized by a poor prognosis, with a median survival of 2 years. In a recent analysis on PC frequency in the elderly population, it has been shown that older patients are more likely to present with very advanced disease and to have a greater risk of death from PC than other competing causes.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore SECS-S/01 - Statistica
English
Bone metastases; CRPC; Elderly; Geriatric assessment; 223Ra-dichloride
DE VINCENTIS, G., Follacchio, G.a., Frantellizzi, V., Prelaj, A., Farcomeni, A., Giuli, A., et al. (2018). 223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 30(6), 677-680 [10.1007/s40520-017-0826-4].
DE VINCENTIS, G; Follacchio, Ga; Frantellizzi, V; Prelaj, A; Farcomeni, A; Giuli, A; Vincenzo, B; Tomao, S
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
De Vincentis_223Ra-dichloride_2018.pdf

non disponibili

Dimensione 515.64 kB
Formato Adobe PDF
515.64 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/222169
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 19
social impact